- $68.66m
- $43.24m
- $0.41m
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake
U.S. STOCKS ON THE MOVE-WhiteHawk, Mirum Pharmaceuticals, Nvidia
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
Brief: Medicinova Announces Completion Of Last Patient, Last Visit In The Double-Blind Portion Of The Phase 2B/3 Combat-Als Trial Of Mn-166
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
MediciNova Inc reports results for the quarter ended June 30 - Earnings Summary
MediciNova Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Medicinova Inc - On Dec 29, Entered $50 Million Equity Distribution Agreement With Lucid Capital Markets- SEC Filing
Brief: MediciNova Completes Patient Enrollment In MN-001 Trial For Tipelukast In MN-001-NATG-202 Study
Brief: Medicinova Announces Poster Presentation Of COMBAT-ALS Clinical Trial At The 36Th International Symposium On ALS/MND
Brief: MediciNova Provides Shareholder Update on Key Developments
Brief: MediciNova Files Prospectus For Sale Of Up To 25 Million Shares By Selling Stockholder
MediciNova Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Medicinova Provides Enrollment Update For Ongoing Als And Hypertriglyceridemia Clinical Trials
MediciNova Inc reports results for the quarter ended March 31 - Earnings Summary